AtlasXomics, founded to revolutionize spatial-omics sequencing, focuses on applications in oncology, neurology, and aging. The company offers a pioneering comprehensive spatial epigenome solution at cellular resolution, enabling detailed tissue analysis and identification of unique cell populations without bias. Their technology facilitates genome-wide mapping of cell populations for regulatory elements, uncovering essential mechanisms of tissue biology.
Notable affiliations include collaborations with leading research labs to map the epigenome in various tissues. Key achievements include the development of the first comprehensive spatial epigenome solution, significantly advancing the field of spatial biology. AtlasXomics' impact is evident in its contributions to understanding complex biological processes and potential therapeutic targets in critical areas such as cancer and neurodegenerative diseases.
